Latest / Community Health Media
Dr. Aditya Bardia and Dr. Reena Callahan - Redefining HER2 Classifications and Treatments
In this insightful CHM Conversations episode, Drs. Callahan & Bardia delve deep into the evolving definitions of HER2 positivity (and negativity, or lack of HER2) in breast cancer and the transformative impact of trastuzumab deruxtecan (T-DXd) especially in metastatic cases.
From groundbreaking historical discoveries to recent clinical trial advancements, they critically examine how HER2 classifications, have moved on from binary to a continuum from low to even ultra-low expression and are reshaping therapeutic paradigms and patient care decisions.
Key insights into managing brain metastases…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.